AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16103515 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous glucose
Number of subjects: 14
Study 16103515 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 14
Study 12270254 — intervention group
Group type: EXPERIMENTAL
Intervention: Large porous particles with MMAD approximately equal to 3 microm
Number of subjects: 0
Study 12270254 — intervention group
Group type: EXPERIMENTAL
Intervention: Large porous particles with MMAD approximately equal to 5 microm
Number of subjects: 0
Study 12270254 — intervention group
Group type: EXPERIMENTAL
Intervention: AIR delivery system
Number of subjects: 0
Study 12270254 — intervention group
Group type: COMPARATOR
Intervention: Dry powder inhalers (DPI)
Number of subjects: 0
Study 10396719 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0% lidocaine
Number of subjects: 20
Study 10396719 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% lidocaine
Number of subjects: 20
Study 10396719 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine
Number of subjects: 20
Study 10396719 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125% bupivacaine
Number of subjects: 20
Study 10396719 — intervention group
Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 20
Study 10396719 — intervention group
Group type: COMPARATOR
Intervention: Untreated whole blood
Number of subjects: 20
Study 8579978 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 2290270 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional IMN tablets (Monisid, Bulgaria)
Number of subjects: 20
Study 2290270 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting IMN tablets (Olicard, FRG)
Number of subjects: 20
Study 2290270 — intervention group
Group type: COMPARATOR
Intervention: Isosorbide dinitrate (ID)
Number of subjects: 20
Study 7338570 — intervention group
Group type: EXPERIMENTAL
Intervention: Bumetanide (various doses in study 1 and 1 or 2 mg in study 2)
Number of subjects: 56
Study 7338570 — intervention group
Group type: COMPARATOR
Intervention: Furosemide (40 or 80 mg in study 2)
Number of subjects: 56
Study 30621211 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented Milk Product (FMP) containing Bifidobacterium animalis subsp. lactis CNCM I‐2494
Number of subjects: 538
Study 29880794 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal iron deficiency (ID)
Number of subjects: 751
Study 29880794 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-iron deficient (non-ID) mothers
Number of subjects: 751
Study 29880794 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo arm)
Number of subjects: 751
Study 27438319 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 mg of ticagrelor twice daily
Number of subjects: 21162
Study 27438319 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg of ticagrelor twice daily
Number of subjects: 21162
Study 27438319 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21162
Study 25196041 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg of nicotine gum
Number of subjects: 60
Study 25196041 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 21896498 — intervention group
Group type: COMPARATOR
Intervention: Prescribed effluent rate of 20 mL/kg/h (standard dose)
Number of subjects: 200
Study 21896498 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescribed effluent rate of 35 mL/kg/h (high dose)
Number of subjects: 200
Study 19126058 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% pyrithione zinc (PTZ) shampoo
Number of subjects: 722
Study 19126058 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% pyrithione zinc (PTZ) shampoo
Number of subjects: 722
Study 19126058 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo control shampoo
Number of subjects: 722
Study 16797823 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopy
Number of subjects: 127
Study 16797823 — intervention group
Group type: COMPARATOR
Intervention: Minilaparotomy
Number of subjects: 127
Study 16797823 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopy (subgroup with cysts > 7 cm)
Number of subjects: 127
Study 16832816 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib at doses of 1.0 mg/m2, 1.3 mg/m2, or 1.5 mg/m2 on Days 1, 4, 8, and 11 of a 21-day treatment cycle for a maximum of 9 cycles
Number of subjects: 22
Study 16832816 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib at 1.5 mg/m2
Number of subjects: 22
Study 16832816 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib (all doses)
Number of subjects: 22
Study 12516653 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG treatment
Number of subjects: 41
Study 12516653 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 41
Study 10208253 — intervention group
Group type: EXPERIMENTAL
Intervention: High carbohydrate (CHO) diet (70% CHO)
Number of subjects: 12
Study 10208253 — intervention group
Group type: COMPARATOR
Intervention: Low carbohydrate (CHO) diet (40% CHO)
Number of subjects: 12
Study 10208253 — intervention group
Group type: EXPERIMENTAL
Intervention: High CHO diet
Number of subjects: 12
Study 7628204 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered lidocaine with sodium bicarbonate
Number of subjects: 46
Study 7628204 — intervention group
Group type: COMPARATOR
Intervention: Unbuffered lidocaine
Number of subjects: 46
Study 2692653 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide 5 mg/kg/day for six days, first dose given immediately after mastectomy.
Number of subjects: 1026
Study 2692653 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant chemotherapy (control group).
Number of subjects: 1026
Study 2692653 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide 5 mg/kg/day for six days, given 2-4 weeks after mastectomy (in a parallel study with 110 patients).
Number of subjects: 1026
Study 786428 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 212
Study 786428 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 212
Study 31422028 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 664
Study 31422028 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel
Number of subjects: 664
Study 29120206 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness plus present control intervention
Number of subjects: 365
Study 29120206 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness only intervention
Number of subjects: 365
Study 29120206 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress management information condition (active comparison)
Number of subjects: 365
Study 29120206 — intervention group
Group type: COMPARATOR
Intervention: Mindfulness plus present control and stress management conditions
Number of subjects: 365
Study 26491824 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g myo‐inositol, 5 mg monacolin K, 400 mg lipoic acid for 6 months
Number of subjects: 30
Study 26491824 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g myo‐inositol, 10 mg monacolin K, 800 mg lipoic acid for 6 months
Number of subjects: 30
Study 23258817 — intervention group
Group type: EXPERIMENTAL
Intervention: Home monitoring (HM) with redundant notifications
Number of subjects: 908
Study 23258817 — intervention group
Group type: EXPERIMENTAL
Intervention: Home monitoring (HM) with single transmissions
Number of subjects: 908
Study 23258817 — intervention group
Group type: EXPERIMENTAL
Intervention: Home monitoring (HM)
Number of subjects: 908
Study 21500907 — intervention group
Group type: EXPERIMENTAL
Intervention: Practicing positive activities (expressing optimism and gratitude)
Number of subjects: 0
Study 21500907 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 18325853 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief intervention (all patients received this); patient satisfaction ratings >or=3.7 on 4-point scale.
Number of subjects: 1483
Study 18325853 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive sexual risk reduction workshop (attended by 56% of invited patients); satisfaction ratings >or=3.6 on 4-point scale.
Number of subjects: 1483
Study 18325853 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up assessments at 3, 6, and 12 months.
Number of subjects: 1483
Study 18325853 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior change and incident STIs assessed through ACASIs and urine specimens.
Number of subjects: 1483
Study 16627865 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescein-enhanced autofluorescence thoracoscopy (FEAT)
Number of subjects: 29
Study 16627865 — intervention group
Group type: EXPERIMENTAL
Intervention: White light thoracoscopy (WLT)
Number of subjects: 29
Study 16627865 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal subjects)
Number of subjects: 29
Study 14520767 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.8% hypertonic saline injected into the anterior temporalis muscle
Number of subjects: 15
Study 14520767 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.8% hypertonic saline injected into the masseter, lateral pterygoid, medial pterygoid, and anterior digastric muscles
Number of subjects: 15
Study 11576047 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine
Number of subjects: 58
Study 11576047 — intervention group
Group type: COMPARATOR
Intervention: 1% mepivacaine
Number of subjects: 58
Study 9512261 — intervention group
Group type: EXPERIMENTAL
Intervention: Double test (free beta-HCG and alpha-fetoprotein)
Number of subjects: 2539
Study 9512261 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple tests (total HCG, alpha-fetoprotein, unconjugated oestriol)
Number of subjects: 2539
Study 9512261 — intervention group
Group type: COMPARATOR
Intervention: Triple tests (free beta-HCG, alpha-fetoprotein, unconjugated oestriol)
Number of subjects: 2539
Study 7519976 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine 0.4 mg/kg per dose, 10 or 11 doses at 30 min intervals (total dose range 233-408 mg)
Number of subjects: 20
Study 7519976 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine days
Number of subjects: 20
Study 7519976 — intervention group
Group type: COMPARATOR
Intervention: Control days
Number of subjects: 20
Study 7519976 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine administration
Number of subjects: 20
Study 2846113 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (heparin fragment), first dose given the evening before surgery, further doses every evening thereafter.
Number of subjects: 1002
Study 2846113 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (heparin fragment)
Number of subjects: 1002
Study 2846113 — intervention group
Group type: COMPARATOR
Intervention: Conventional low-dose heparin
Number of subjects: 1002
Study 1149632 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor VIII concentrates (n=8)
Number of subjects: 15
Study 1149632 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion treatment
Number of subjects: 15
Study 1149632 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of haemostatic and anti-inflammatory substances, physiotherapy, and orthopaedic means
Number of subjects: 15
Study 31105703 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab (GM) treatment
Number of subjects: 0
Study 31105703 — intervention group
Group type: COMPARATOR
Intervention: GM untreated group
Number of subjects: 0
Study 27853886 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based isometric exercise training (IET)
Number of subjects: 28
Study 27853886 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 28
Study 25969139 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (3+3mg)
Number of subjects: 82
Study 25969139 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 23171351 — intervention group
Group type: COMPARATOR
Intervention: Formocresol (FC)
Number of subjects: 100
Study 23171351 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral trioxide aggregate (MTA)
Number of subjects: 100
Study 23171351 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium hypochlorite (NaOCl)
Number of subjects: 100
Study 23171351 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric sulphate
Number of subjects: 100
Study 21762532 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal smoking cessation intervention
Number of subjects: 200
Study 21762532 — intervention group
Group type: COMPARATOR
Intervention: Hospital smoking care only
Number of subjects: 200
Study 19226238 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive joint mobilisation of shoulder region joints
Number of subjects: 90
Study 19226238 — intervention group
Group type: COMPARATOR
Intervention: Advice and exercise alone
Number of subjects: 90
Study 17118828 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical cooling with ice‐slush
Number of subjects: 60
Study 17118828 — intervention group
Group type: COMPARATOR
Intervention: Crystalloid antegrade cardioplegia
Number of subjects: 60
Study 15302008 — intervention group
Group type: EXPERIMENTAL
Intervention: Tezosentan 5 mg/h
Number of subjects: 130
Study 15302008 — intervention group
Group type: EXPERIMENTAL
Intervention: Tezosentan 25 mg/h
Number of subjects: 130
Study 15302008 — intervention group
Group type: EXPERIMENTAL
Intervention: Tezosentan 1 mg/h
Number of subjects: 130
Study 15302008 — intervention group
Group type: EXPERIMENTAL
Intervention: Tezosentan 0.2 mg/h
Number of subjects: 130
Study 15302008 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 11762740 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk-based dietary supplements (powder reconstituted in fat-free milk)
Number of subjects: 10
Study 11762740 — intervention group
Group type: EXPERIMENTAL
Intervention: Ready-to-drink milk-based supplement
Number of subjects: 10
Study 11762740 — intervention group
Group type: COMPARATOR
Intervention: Low-lactose control preparations
Number of subjects: 10
Study 9420452 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose micronutrient supplement containing trace minerals (zinc and selenium)
Number of subjects: 0
Study 9420452 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamins/provitamins (vitamin C, alpha-tocopherol, and beta-carotene)
Number of subjects: 0
Study 9420452 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29483583 — intervention group
Group type: COMPARATOR
Intervention: TE regimen (docetaxel and epirubicin)
Number of subjects: 125
Study 29483583 — intervention group
Group type: EXPERIMENTAL
Intervention: TEL regimen (docetaxel, epirubicin, and lobaplatin)
Number of subjects: 125
Study 23670810 — intervention group
Group type: EXPERIMENTAL
Intervention: Aboulker stent (A)
Number of subjects: 24
Study 23670810 — intervention group
Group type: EXPERIMENTAL
Intervention: Silastic stent (S)
Number of subjects: 24
Study 23670810 — intervention group
Group type: EXPERIMENTAL
Intervention: Type of stent used
Number of subjects: 24
Study 22689694 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory disturbance index (RDI)
Number of subjects: 126
Study 22689694 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep efficiency
Number of subjects: 126
Study 22689694 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum cortisol (in women)
Number of subjects: 126
Study 22689694 — intervention group
Group type: EXPERIMENTAL
Intervention: Epworth sleepiness score (in women)
Number of subjects: 126
Study 22689694 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple regression model including RDI, serum cortisol, and urinary norepinephrine
Number of subjects: 126
Study 19399562 — intervention group
Group type: EXPERIMENTAL
Intervention: External pancreatic duct stent
Number of subjects: 0
Study 19399562 — intervention group
Group type: COMPARATOR
Intervention: Octreotide
Number of subjects: 0
Study 19399562 — intervention group
Group type: COMPARATOR
Intervention: Internal pancreatic duct stents
Number of subjects: 0
Study 19399562 — intervention group
Group type: COMPARATOR
Intervention: Topical or intraductal fibrin glue
Number of subjects: 0
Study 16728244 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxide paste with lentulo‐spiral filler, removed with #15 K‐file agitated irrigation with 17% EDTA (group 2)
Number of subjects: 47
Study 16728244 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxide paste with lentulo‐spiral filler, removed with ultrasonically agitated irrigation with 17% EDTA (group 3)
Number of subjects: 47
Study 16728244 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate filling with Resilon (group 1)
Number of subjects: 47
Study 16728244 — intervention group
Group type: COMPARATOR
Intervention: Positive control with Resilon master point size 40/.04 without sealer
Number of subjects: 47
Study 15019671 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 1628
Study 15019671 — intervention group
Group type: COMPARATOR
Intervention: Control (non-recipients of clopidogrel)
Number of subjects: 1628
Study 11560557 — intervention group
Group type: EXPERIMENTAL
Intervention: RTV : SQV 200 : 800 mg (E)
Number of subjects: 8
Study 11560557 — intervention group
Group type: COMPARATOR
Intervention: RTV : SQV 400 : 400 mg (B)
Number of subjects: 8
Study 11560557 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination regimens (E, F, G)
Number of subjects: 8
Study 9483394 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound screening during pregnancy
Number of subjects: 0
Study 9483394 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound exposure
Number of subjects: 0
Study 9483394 — intervention group
Group type: COMPARATOR
Intervention: Non-exposure to ultrasound screening
Number of subjects: 0
Study 8139085 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine
Number of subjects: 3806
Study 8139085 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3806
Study 2457351 — intervention group
Group type: EXPERIMENTAL
Intervention: Lugol's iodine alone for 10 days pre-operatively (Group I)
Number of subjects: 34
Study 2457351 — intervention group
Group type: COMPARATOR
Intervention: ATD and T4 alone until the time of operation (Group II)
Number of subjects: 34
Study 2457351 — intervention group
Group type: EXPERIMENTAL
Intervention: ATD and T4 continued until the day of operation with 10 days' treatment with Lugol's iodine (Group III)
Number of subjects: 34
Study 30961368 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted message
Number of subjects: 60
Study 30961368 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-inclusive message
Number of subjects: 60
Study 30961368 — intervention group
Group type: EXPERIMENTAL
Intervention: No youth message
Number of subjects: 60
Study 30961368 — intervention group
Group type: COMPARATOR
Intervention: All messages
Number of subjects: 60
Study 30961368 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention paid to the message
Number of subjects: 60
Study 31757067 — intervention group
Group type: EXPERIMENTAL
Intervention: Served smaller portion size (Study 2)
Number of subjects: 461
Study 31757067 — intervention group
Group type: COMPARATOR
Intervention: Served larger portion size (Study 2)
Number of subjects: 461
Study 31757067 — intervention group
Group type: COMPARATOR
Intervention: Visual exposure to portion size (Study 1)
Number of subjects: 461
Study 28644822 — intervention group
Group type: EXPERIMENTAL
Intervention: Lay-led Chronic Pain Self-Management Programme (CPSMP)
Number of subjects: 424
Study 28644822 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 424
Study 26318271 — intervention group
Group type: EXPERIMENTAL
Intervention: MBCT + mADM (n=33)
Number of subjects: 68
Study 26318271 — intervention group
Group type: COMPARATOR
Intervention: mADM alone (n=35)
Number of subjects: 68
Study 23517506 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive management (4 weekly review) for 48 weeks
Number of subjects: 206
Study 23517506 — intervention group
Group type: COMPARATOR
Intervention: Standard care (12 weekly review) for 48 weeks
Number of subjects: 206
Study 23517506 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness analysis at 12, 24, and 28 weeks
Number of subjects: 206
Study 22051756 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (8 mg i.v.) in non-diabetics (n = 20)
Number of subjects: 70
Study 22051756 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (8 mg i.v.) in type 2 diabetics (n = 15)
Number of subjects: 70
Study 22051756 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline in non-diabetics (control group, n = 20)
Number of subjects: 70
Study 22051756 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline in type 2 diabetics (control group, n = 15)
Number of subjects: 70
Study 18485394 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin 80 mg/50 ml normal saline plus delayed bacillus Calmette‐Guerin (5 x 10^8 colony‐forming units in 50 ml saline)
Number of subjects: 161
Study 18485394 — intervention group
Group type: COMPARATOR
Intervention: Delayed bacillus Calmette‐Guerin alone
Number of subjects: 161
Study 18485394 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin plus delayed bacillus Calmette‐Guerin
Number of subjects: 161
Study 16778364 — intervention group
Group type: EXPERIMENTAL
Intervention: lansoprazole, 30 mg/day
Number of subjects: 30
Study 16778364 — intervention group
Group type: COMPARATOR
Intervention: roxatidine, 150 mg/day
Number of subjects: 30
Study 15589851 — intervention group
Group type: EXPERIMENTAL
Intervention: i.m. P plus phytoestrogens (1,500 mg daily)
Number of subjects: 213
Study 15589851 — intervention group
Group type: COMPARATOR
Intervention: i.m. P (50 mg daily) plus placebo
Number of subjects: 213
Study 11789743 — intervention group
Group type: EXPERIMENTAL
Intervention: Pubovaginal sling
Number of subjects: 46
Study 11789743 — intervention group
Group type: COMPARATOR
Intervention: Burch colposuspension
Number of subjects: 46
Study 8980207 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise training (16 weeks, 4 sessions per week, 30-40 minutes each session at 60%-75% of heart rate reserve)
Number of subjects: 43
Study 8980207 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise training
Number of subjects: 43
Study 8980207 — intervention group
Group type: COMPARATOR
Intervention: Wait-listed control condition
Number of subjects: 43
Study 8512601 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary, physical activity, and educational interventions
Number of subjects: 423